Biotech & Life Sciences
Apptly’s OTCQB Listing Follows a Fresh FDA-Approved Imaging Partnership
Apptly Health Technologies signed a partnership with the maker of the only FDA-approved breast CT system on Tuesday. Two days later, on Wednesday, the company’s stock became tradable to a much larger pool of US investors for the first time. The timing wasn’t a coincidence so much as a pattern; it’s roughly the pace the…
RenovoRx Hits 52-Week High as Revenue and Trial News Align
RenovoRx spent August checking boxes most microcap biotechs take years to check. A pivotal trial finished enrolling. Quarterly revenue kept climbing. A Nasdaq compliance problem got resolved. By month’s end, the stock was sitting at a 52-week high. RenovoRx Hits 52-Week High as Revenue Growth and Trial Enrollment Both Deliver RenovoRx (Nasdaq: RNXT) shares rose…
Capricor Buys More Time on Deramiocel as an Investor Pushes for Board Change
Capricor’s FDA deadline came and went last Saturday with no announcement. Two days later, the company said the agency had granted a three-month extension instead of a decision. The same week, an activist investor sent Capricor’s other shareholders a letter demanding a board shake-up, timed to land in the middle of the company’s most consequential…
Capricor Gains 11% as FDA Pushes Deramiocel Decision to Nov
A three-month delay is not usually something a stock rallies on. Capricor Therapeutics gained 11% anyway. The company’s Duchenne muscular dystrophy therapy just got a longer FDA review instead of a decision, and investors treated the extra scrutiny as a sign the door stayed open rather than a rejection in slow motion. Capricor Gains 11%…
TempraMed’s Panama Deal Is the Latest Piece of a Global Distribution Push
TempraMed’s distributor in Panama didn’t wait for a photo op. The company’s own press release notes a first bulk commercial order already fulfilled into Panamanian clinics and pharmacies, the same week the distribution agreement itself became official. It’s the latest in a string of country and channel additions the small Vancouver medtech company has closed…
OmniAb Jumps 13% on Eli Lilly Ion Channel Collaboration
OmniAb landed a partner with deep pockets on Monday. Acurx Pharmaceuticals landed something smaller but just as telling: a brand name regulators are willing to put on a drug label. Neither event is an approval. Both moved the stock like one. OmniAb Jumps 13% on Eli Lilly Collaboration Worth Up to $370 Million OmniAb (Nasdaq:…
Tenax Therapeutics Stock Craters 90% After Phase 3 Trial Misses Primary Endpoint
Tenax Therapeutics closed at $13.45 on Friday. It opened Monday at $1.77. In between, the company’s only Phase 3 trial reported a treatment difference of 3.5 meters on its primary endpoint, a result so far from significance that seven Wall Street analysts cut their price targets by roughly 90% apiece within a single trading day.…
Faeth Therapeutics Jumps 18% as Cash Grows to $186 Million
Faeth Therapeutics and Veru posted double-digit stock gains on the same Monday, for reasons that had nothing to do with each other. Faeth used its quarterly numbers to show it is sitting on nine times the cash it had six months ago. Veru used its own earnings call to confirm a trial enrolled faster than…
BriaCell’s FDA Clearance for Bria-PROS+ Adds a Fourth Active Immunotherapy
BriaCell just added a fourth active immunotherapy program to a pipeline that already has one candidate in Phase 3. The FDA didn’t blink. Two names covered here last week did get their answers this week, and the answers landed nothing alike, one company watched its stock double, the other is now talking about suing its…
Capricor’s Deramiocel Voted Down 9-3 by FDA Advisory Panel
Nine advisory committee members looked at the same trial data Capricor called a win and voted against it. The 9-3 result on July 29 didn’t kill Capricor’s Duchenne muscular dystrophy program, but it added a real question mark to a therapy the company insists already cleared its bar. INmune Bio spent the same stretch doing…
